Physician profile
Arthur B Flick
NPI 1952435828
$334.22
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $81.60 · 2021: $88.20 · 2022: $20.21 · 2024: $23.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $74.22 | 2019 | |
| Daiichi Sankyo INC. | $34.62 | 2019-2020 | |
| Melinta Therapeutics, LLC | $32.46 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $31.19 | 2020-2021 | |
| Lilly USA, LLC | $26.08 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $23.05 | 2024 | |
| Abbott Laboratories | $20.21 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.01 | 2020 | |
| Surmodics, INC. | $18.04 | 2021 | |
| Boston Scientific Corporation | $15.48 | 2020 | |
| Novo Nordisk INC | $14.43 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.31 | 2021 | |
| Smith+Nephew, INC. | $11.12 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Flick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.